Author:
Daaboul Yazan,Halaby Rim,Korjian Serge,Bahaa Eldin Hesham,Lemor Alejandro,Singh Kiran,Susheela Ammu Thampi,Ponnusamy Vignesh,Beereddy Deepika,Hernández-Elenes Jesús R.,Poongkunran Mugilan,Ajari Ogheneochuko W.,Alvarado Alonso,Gibson C. Michael
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference46 articles.
1. Brotman I. Anticoagulants in myocardial infarction acute and long-term therapy. Am J Cardiol. 1958;1(2):260–70.
2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349-60.
3. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339(23):1665–71.
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
5. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89.